drugset / Trial / NCT00431873
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly to patients with refractory chronic lymphocytic leukemia.
Timeline
- Start
- 2007-01
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mocetinostat | Small molecule | — | Oral |